Telonostix
Telomere length analysis services for clinical research, diagnostic screening and therapeutic development teams
Highlights
- New on EvolcAdded 2026-11-15
About Telonostix
TeloNostiX provides high-resolution telomere length analysis using Single Telomere Length Analysis (STELA), including high-throughput and single-molecule testing. Its services support research in telomere biology, cancer, cellular therapies and telomere-related disorders.
Customers include NHS centres, research groups and pharmaceutical and biotechnology companies. The company provides bespoke and high-throughput laboratory analysis services; its HT-STELA service is accredited to ISO/IEC 17025:2017 by UKAS.
TeloNostiX is based in Cardiff and was founded in 2017, according to its company profile. It provides testing to NHS centres across the UK and centres in Europe, Australia and New Zealand.
Product: High-throughput and single-molecule STELA services for high-resolution telomere length analysis.
Jobs at Telonostix
Leadership
- Chris Fegan · Chief Medical OfficerSource: company website
- Chris Pepper · Chief Scientific OfficerSource: company website
- Joe Birkett · Chief Executive OfficerSource: company website
- Duncan Baird · Chief Technology OfficerSource: company website
More biotech & pharma companies
Tepnel Pharma Services
Pharmaceutical testing and analytical laboratory services for drug developers and pharmaceutical companiesNew on EvolcTeva UK
Biopharmaceutical company supplying innovative, generic and biosimilar medicines to patients and healthcare providers in the UKThe Electrospinning Company
Electrospun biomaterials and coatings for medical device developers, from feasibility studies through regulated manufacturingNew on EvolcTheolytics
Develops oncolytic adenovirus immunotherapies for patients with solid tumours and cancers of high unmet needTheramex
Specialty pharmaceuticals for women’s health, including contraception, fertility, menopause and osteoporosis treatmentsRemote-friendlyThirtyfivebio
Develops GPR35-inhibiting drug candidates that protect gut epithelial cells in ulcerative colitis patientsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- DudaHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.